Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
QD community oral or SC MOTS-c Daily SC, often 5 days on / 2 off AOD-9604 Daily SC Attribute Max studied dose SLU-PP-332 50 mg/kg BID (mouse, 28 days) MOTS-c 5-15 mg/kg (mouse) AOD-9604 1-5 mg/day in human Phase 2 Attribute Peak efficacy signal SLU-PP-332 ~25-30% fat-mass reduction in DIO mice over 28 days MOTS-c Improved insulin sensitivity in aged mice AOD-9604 Modest fat-loss signal in human Phase 2
Semaglutide and tirzepatide both bill using J3490 (Drug, Not Otherwise Classified) or J3590 (Non-Covered Drug) depending on the payer
Research Situations: This chemical matrix is strictly designed to monitor metabolic alterations, hepatic lipid clearance, and cellular synthesis pathways within controlled laboratory environments
Ensure the medical record includes: neurologist diagnosis statement, NCS/EMG reports, treatment plan, and response documentation before coding G61.81 for inpatient or outpatient IVIG claims
US$ 23.74
US$ 25.45
US$ 21.80
US$ 23.93
